Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $10.57 Average Price Target from Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned an average recommendation of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $10.57.

A number of analysts have recently issued reports on the company. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a report on Friday, March 7th. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday. Finally, Lake Street Capital cut their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th.

Hedge Funds Weigh In On Aquestive Therapeutics

Several large investors have recently added to or reduced their stakes in AQST. Bank of America Corp DE increased its stake in Aquestive Therapeutics by 905.2% during the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock valued at $2,457,000 after purchasing an additional 621,614 shares during the last quarter. State Street Corp boosted its holdings in shares of Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after buying an additional 512,682 shares during the period. Stifel Financial Corp grew its position in shares of Aquestive Therapeutics by 315.4% during the 4th quarter. Stifel Financial Corp now owns 398,561 shares of the company’s stock valued at $1,419,000 after buying an additional 302,617 shares during the last quarter. Harvey Capital Management Inc. raised its stake in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock worth $952,000 after acquiring an additional 249,790 shares during the period. Finally, Verition Fund Management LLC bought a new position in Aquestive Therapeutics in the third quarter worth about $995,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Stock Up 6.3 %

NASDAQ AQST opened at $3.04 on Monday. Aquestive Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $5.80. The business has a 50 day moving average price of $2.98 and a two-hundred day moving average price of $3.91. The stock has a market cap of $300.57 million, a PE ratio of -6.76 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. Sell-side analysts anticipate that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.